We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
+4.37%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$338M
AUM Growth
-$1.49B
(-81%)
Cap. Flow
-$1.49B
Cap. Flow
% of AUM
-440.09%
Top 10 Holdings %
Top 10 Hldgs %
50.11%
Holding
82
New
26
Increased
20
Reduced
13
Closed
22
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$21.3M |
| 2 |
Integra LifeSciences
IART
|
+$13.4M |
| 3 |
AbbVie
ABBV
|
+$12.8M |
| 4 |
AdaptHealth
AHCO
|
+$9.39M |
| 5 |
Encompass Health
EHC
|
+$8.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Medtronic
MDT
|
+$6.95M |
| 2 |
ICU Medical
ICUI
|
+$6.55M |
| 3 |
Labcorp
LH
|
+$6.3M |
| 4 |
Centene
CNC
|
+$5.94M |
| 5 |
SI-BONE Inc
SIBN
|
+$5.57M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 83.24% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ADAP
26
DELISTED
Adaptimmune Therapeutics
ADAP
| $4.58M | 1.36% |
574,502
+91,399
| +19% | +$800K |
|
27
Mustang Bio
MBIO
$4.36M
| $4.48M | 1.33% |
1,897
+872
| +85% | +$2.15M |
|
|
28
Centene
CNC
$31.7B
| $4.34M | 1.28% |
74,408
-95,649
| -56% | -$5.94M |
|
|
PDCO
29
DELISTED
Patterson Companies, Inc.
PDCO
| $3.94M | 1.16% |
+163,415
| New | +$4.16M |
|
30
Cartesian Therapeutics
RNAC
$257M
| $3.75M | 1.11% |
50,402
-8,909
| -15% | -$683K |
|
31
Aclaris Therapeutics
ACRS
$851M
| $3.68M | 1.09% |
1,432,817
-295,970
| -17% | -$662K |
|
|
VAPO
32
DELISTED
Vapotherm, Inc. Common Stock
VAPO
| $3.65M | 1.08% |
+15,709
| New | +$4.53M |
|
33
Haemonetics
HAE
$3.86B
| $3.63M | 1.07% |
41,607
+12,670
| +44% | +$1.11M |
|
34
PetMed Express
PETS
$42.1M
| $3.35M | 0.99% |
+105,895
| New | +$3.5M |
|
35
Quest Diagnostics
DGX
$26.3B
| $3.33M | 0.98% |
+29,041
| New | +$3.43M |
|
|
CALT
36
DELISTED
Calliditas Therapeutics AB American Depositary Shares
CALT
| $2.67M | 0.79% |
111,467
-48,751
| -30% | -$1.14M |
|
37
Prothena Corp
PRTA
$449M
| $2.63M | 0.78% |
262,773
-141,020
| -35% | -$1.7M |
|
38
MacroGenics
MGNX
$255M
| $2.45M | 0.73% |
+97,374
| New | +$2.66M |
|
|
TBIO
39
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $2.4M | 0.71% |
+176,710
| New | +$2.72M |
|
40
Fate Therapeutics
FATE
$290M
| $2.25M | 0.66% |
56,210
-4,682
| -8% | -$163K |
|
41
Alcon
ALC
$33.9B
| $2.19M | 0.65% |
+38,373
| New | +$2.26M |
|
|
APTO
42
DELISTED
Aptose Biosciences, Inc.
APTO
| $2.07M | 0.61% |
+767
| New | +$1.91M |
|
43
Immunic
IMUX
$198M
| $2.06M | 0.61% |
+11,091
| New | +$1.82M |
|
44
Bio-Rad Laboratories Class A
BIO
$9.16B
| $2.02M | 0.6% |
3,916
+411
| +12% | +$208K |
|
|
FPRX
45
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $1.98M | 0.59% |
421,398
+184,224
| +78% | +$936K |
|
46
Kiniksa Pharmaceuticals
KNSA
$5.97B
| $1.8M | 0.53% |
+117,480
| New | +$2.21M |
|
47
DaVita
DVA
$11.5B
| $1.8M | 0.53% |
+21,002
| New | +$1.79M |
|
|
LMNX
48
DELISTED
Luminex Corp
LMNX
| $1.79M | 0.53% |
+68,131
| New | +$2.09M |
|
|
ALBO
49
DELISTED
Albireo Pharma Inc
ALBO
| $1.74M | 0.51% |
+52,131
| New | +$1.52M |
|
50
Arcturus Therapeutics
ARCT
$173M
| $1.48M | 0.44% |
+34,485
| New | +$1.71M |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q3 2020 Portfolio in Review
As of Q3 2020, Endurant Capital Management held 82 positions worth $338M, down 81% from $1.82B the previous quarter. Its ten largest holdings account for 50% of the portfolio.
Endurant Capital Management withdrew a net $1.49B in Q3 2020, closing 22 positions and reducing 13 holdings. Its most notable exit was Medtronic, an estimated $6.95M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 12% a quarter earlier, followed by Industrials.
Against the trend, Endurant Capital Management opened a new position in Integra LifeSciences worth $13.3M.
- Endurant Capital Management's largest Q3 2020 buy was Integra LifeSciences: 281,608 shares worth $13.3M.
- Endurant Capital Management added most to Bristol-Myers Squibb in Q3 2020, an estimated $21.3M increase.
- Endurant Capital Management's biggest Q3 2020 reduction was Centene, cutting an estimated $5.94M.
- Endurant Capital Management fully exited Medtronic in Q3 2020, selling an estimated $6.95M.
- Endurant Capital Management's ten largest holdings make up 50% of its $338M portfolio in Q3 2020.
- Endurant Capital Management opened 26 new positions and closed 22 in Q3 2020.
- Endurant Capital Management's portfolio value fell 81% quarter-over-quarter to $338M.
Based on Endurant Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.